PharmTech News

Articles

The companies launched Onduo, a joint venture focused on developing solutions to assist patients with Type 2 diabetes.

Sanofi and Verily Launch Onduo

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

Results show the drug was effective at reducing the risk of uveitic flare or visual impairment.

Results Released for Adalimumab’s Uveitis Trial

Allergan acquired clinical-stage gene-therapy company, RetroSense Therapeutics, for $60 million.

Allergan Acquires RetroSense Therapeutics

The company established a dedicated research center in Bangalore, India for Amgen.

Syngene International Establishes R&D Center for Amgen

Results from a small Phase Ib trial with Biogen’s aducanumab showed the drugs potential as an investigational treatment for patients with Alzheimer’s disease (AD). Researchers from the University of Zurich evaluated the efficacy of aducanumab in 165 patients with early-stage AD. At the conclusion of 54 weeks, the researchers reported seeing a dose-dependent reduction of amyloid-beta in patient’s brains compared to a placebo. Exploratory results indicate the drug may also slow clinical decline.

Aducanumab Shows Potential in Small Phase I Trial

Sandoz won FDA approval for its biosimilar version of Enbrel.

Sandoz Enbrel Biosimilar Gets Okay from FDA

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Can Competition Block Excessive Pharma Price Hikes? EpiPen Saga Shows It’s Hard

Competition and Drug Pricing

The company will launch a generic version of EpiPen at the price of $300 for a two-pack.

Mylan to Launch Generic Version of EpiPen

The initiative targets countries with less developed and evolving healthcare systems such as Latin America, South East Asia, and Africa.

Takeda Launches Medicines Access Strategy in Regions with High Unmet Medical Needs

Ranking members of the Senate Judiciary Committee called on Mylan to explain its decision to raise the price of EpiPens nearly 400%.

Bio/Pharma News